Tracer library / [11C]UCB-J

Structure of UCB-J (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 139953895

[11C]UCB-J

Also written as [11C]UCB-J; [C-11]UCB-J; UCB-J

Radionuclide: C-11 t½ 20.36 min
Modality: PET
Production route: —
Stage: —
Syntheses indexed: 4

Epilepsy

What it is

Compound class: Pyrrolidinone SV2A ligand (trifluoroborate-derived, 11C-methylated small molecule)
Target / mechanism: Targets synaptic vesicle glycoprotein 2A (SV2A) to visualize synaptic density PMID 42154186
Clinical application: Imaging synaptic density in patients with epilepsy and other neurologic, neurodegenerative, or psychiatric conditions PMID 42154186
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Synthra RNplus Synthra	custom manifold	HPLC+SPE	11 ± 1% (nondecay corrected); 35 ± 4% (decay corrected) not corrected	100	(R)-trifluoro(4-((2-oxo-4-(3,4,5-trifluoroph…(R)-trifluoro(4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl)methyl)pyridin-1-ium-3-yl)borate (UCB-J precursor) UCB, Belgium	32027052 2020 J Labelled Comp Radiopharm Synthra RNPlus synthesizer - The nondecay corrected radiochemical yield was 11 ± 1% (n = 7) and if decay corrected 35 ± 4% (n = 7).
In-house / custom built Siemens / CTI	—	—	72 ± 10% decay-corrected	—	—	33238289 2021 Nature our 11C-labeling protocol was independently performed by Siemens Molecular Imaging Biomarker Research in North Wales, PA with a robotic, remote-controlled radiosynthetic setup for the preparation of [11C]UCB-J - yielding 72 ± 10% RCY (dc) and 19 ± 2% RCY (ndc) (n = 4) of the radioligand
In-house / custom built in-house	custom manifold	HPLC+SPE	26.7 ± 5.6% decay-corrected	99.3 ± 0.2%	(R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-t…(R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-l)methyl)-pyridin-1-ium fluoride PharmaSynth AS, Tartu, Estonia	42154186 2026 EJNMMI Radiopharm Chem we present an in-house-built device for [11C]UCB-J production from [11C]CH3I and a suitably treated boronated precursor - 56 using new preparative HPLC method protocol 2 (RCY 26.7 ± 5.6%)
Synthra MeIplus Synthra	—	HPLC+SPE	21.1 ± 6.1% decay-corrected	99.4 ± 0.2%	(R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-t…(R)-3-(difluoroboranyl)-4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-l)methyl)-pyridin-1-ium fluoride PharmaSynth AS, Tartu, Estonia	42154186 2026 EJNMMI Radiopharm Chem [11C]CH3I production using the Synthra MeIplus Research device (Synthra GmbH, Hamburg, Germany) - 94 of these syntheses were performed using protocol 1 as preparative HPLC method (RCY 21.1 ± 6.1%)

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: PharmaSynth AS, UCB
Typical final purification: —

Need this precursor?We can point you to suppliers for [11C]UCB-J, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrity

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [11C]UCB-J.

Get in touch

Notes

Added from reverse module search (stage 6); 1 article(s) with C-11. Merged stage 17: +4 article(s) from c11-synvest1 (row was a mislabelled duplicate of [11C]UCB-J); combined count 5. Compound class inferred from precursor name (not stated outright) -- PMID 32027052: '(R)-trifluoro(4-((2-oxo-4-(3,4,5-trifluorophenyl)pyrrolidin-1-yl)methyl)pyridin-1-ium-3-yl)borate (UCB-J precursor)'.